Loftus J P, Nagorney D M, Ilstrup D, Kunselman A R
Department of Surgery, Mayo Clinic, Rochester, Minnesota 55905.
Ann Surg. 1993 Jan;217(1):35-40. doi: 10.1097/00000658-199301000-00007.
Splenectomy has been considered the treatment of choice for patients with bleeding from sinistral portal hypertension (SPH) and varices, but is controversial for asymptomatic patients. To further define the role of splenectomy for SPH, the authors compared the clinical presentations and outcomes of 25 patients treated with splenectomy with those of 12 observed patients. Clinical features were similar except for transfusions administered (60% vs. 25%, p < 0.05), hemoglobin (9.8 +/- 2.2 g/dL vs. 12.5 +/- 2.1 g/dL, p < 0.05), and history of prior bleeding episodes (56% vs. 8%, p < 0.05), splenectomy versus no splenectomy, respectively. At 3 years, neither survival (78% vs. 64%, p = 1.0) nor new or recurrent bleeding (16% vs. 24%, p = 0.2) differed, splenectomy versus no splenectomy, respectively. The authors conclude that in the absence of prior bleeding episodes, anemia, or severe hemorrhage, observation of patients with SPH is justified.
脾切除术一直被认为是治疗左侧门静脉高压(SPH)并伴有静脉曲张出血患者的首选治疗方法,但对于无症状患者存在争议。为了进一步明确脾切除术在SPH治疗中的作用,作者比较了25例行脾切除术患者与12例观察患者的临床表现及治疗结果。除输血情况(60% 对25%,p < 0.05)、血红蛋白水平(9.8 ± 2.2 g/dL对12.5 ± 2.1 g/dL,p < 0.05)以及既往出血史(56% 对8%,p < 0.05)外,脾切除术组与非脾切除术组的临床特征相似。3年后,脾切除术组与非脾切除术组在生存率(78% 对64%,p = 1.0)以及新发或复发出血情况(16% 对24%,p = 0.2)方面均无差异。作者得出结论,在无既往出血史、贫血或严重出血的情况下,对SPH患者进行观察是合理的。